Letermovir tablet + Letermovir IV

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus Infection

Conditions

Cytomegalovirus Infection, Cytomegalovirus Disease

Trial Timeline

Dec 27, 2019 → Oct 6, 2022

NCT ID

NCT04129398

About Letermovir tablet + Letermovir IV

Letermovir tablet + Letermovir IV is a phase 3 stage product being developed by Merck for Cytomegalovirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04129398. Target conditions include Cytomegalovirus Infection, Cytomegalovirus Disease.

What happened to similar drugs?

8 of 20 similar drugs in Cytomegalovirus Infection were approved

Approved (8) Terminated (2) Active (10)

✅LetermovirMerckApproved

✅Single arm (ganciclovir and valganciclovir)RocheApproved

✅Ganciclovir + valganciclovir [Valcyte]RocheApproved

✅ValganciclovirRocheApproved

✅valganciclovir [Valcyte]RocheApproved

✅Valganciclovir + CMV hyperimmune globulin + ValganciclovirCSLApproved

✅CytogamKamadaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04129398	Phase 3	Completed	Dec 27, 2019	Oct 6, 2022	Cytomegalovirus Infection

Competing Products

20 competing products in Cytomegalovirus Infection

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40
Letermovir	Merck	Phase 2	35